Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $46.23 | 2 | 50.5% |
| Education | $45.37 | 3 | 49.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $24.73 | 1 | $0 (2017) |
| Merck Sharp & Dohme Corporation | $21.50 | 1 | $0 (2018) |
| PFIZER INC. | $21.00 | 1 | $0 (2021) |
| Karyopharm Therapeutics Inc. | $12.45 | 1 | $0 (2020) |
| Gilead Sciences, Inc. | $11.92 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $32.92 | 2 | PFIZER INC. ($21.00) |
| 2020 | $12.45 | 1 | Karyopharm Therapeutics Inc. ($12.45) |
| 2018 | $21.50 | 1 | Merck Sharp & Dohme Corporation ($21.50) |
| 2017 | $24.73 | 1 | Genentech USA, Inc. ($24.73) |
All Payment Transactions
5 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/09/2021 | PFIZER INC. | ORGOVYX (Drug) | Education | In-kind items and services | $21.00 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 11/17/2020 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Education | In-kind items and services | $12.45 | General |
| Category: Oncology | ||||||
| 06/19/2018 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $21.50 | General |
| Category: ONCOLOGY | ||||||
| 09/18/2017 | Genentech USA, Inc. | Perjeta (Biological) | Food and Beverage | In-kind items and services | $24.73 | General |
| Category: BioOncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 27 | 1,392 | 39,369 | $1.9M | $769,542 |
| 2020 | 32 | 1,506 | 36,974 | $1.8M | $667,790 |
All Medicare Procedures & Services
61 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2021 | 16 | 14,600 | $870,000 | $489,728 | 56.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 313 | 694 | $204,730 | $67,753 | 33.1% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2021 | 17 | 9,800 | $164,320 | $65,699 | 40.0% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 102 | 386 | $204,580 | $46,905 | 22.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 275 | 524 | $107,420 | $35,687 | 33.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 68 | 114 | $45,030 | $16,746 | 37.2% |
| 96401 | Non-hormonal anti-neoplastic chemotherapy beneath the skin or into muscle | Office | 2021 | 11 | 112 | $33,040 | $7,687 | 23.3% |
| 96417 | Infusion of different chemotherapy drug or substance into a vein up to 1 hour | Office | 2021 | 41 | 104 | $26,000 | $6,229 | 24.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2021 | 36 | 77 | $29,645 | $4,527 | 15.3% |
| 96367 | Infusion into a vein for therapy prevention or diagnosis additional sequential infusion up to 1 hour | Office | 2021 | 64 | 162 | $26,730 | $4,316 | 16.1% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2021 | 17 | 3,250 | $11,245 | $4,062 | 36.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 30 | 30 | $13,650 | $3,762 | 27.6% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 44 | 283 | $25,470 | $3,307 | 13.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 16 | 16 | $9,056 | $2,590 | 28.6% |
| 96415 | Infusion of chemotherapy into a vein | Office | 2021 | 27 | 86 | $9,890 | $2,241 | 22.7% |
| 96375 | Injection of different drug or substance into a vein for therapy, diagnosis, or prevention | Office | 2021 | 52 | 129 | $10,320 | $1,831 | 17.7% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2021 | 40 | 720 | $55,130 | $1,492 | 2.7% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2021 | 23 | 176 | $52,800 | $1,472 | 2.8% |
| J9267 | Injection, paclitaxel, 1 mg | Office | 2021 | 23 | 6,168 | $9,252 | $769.61 | 8.3% |
| 96523 | Irrigation of implanted venous access drug delivery device | Office | 2021 | 16 | 38 | $3,800 | $749.27 | 19.7% |
| 96360 | Hydration infusion into a vein 31 minutes to 1 hour | Office | 2021 | 17 | 23 | $4,600 | $663.74 | 14.4% |
| 96361 | Hydration infusion into a vein | Office | 2021 | 19 | 43 | $3,139 | $486.03 | 15.5% |
| J9045 | Injection, carboplatin, 50 mg | Office | 2021 | 20 | 194 | $21,035 | $400.57 | 1.9% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2021 | 63 | 1,573 | $4,582 | $190.20 | 4.2% |
| 99211 | Established patient outpatient visit, minimal presenting problem | Office | 2021 | 11 | 11 | $605.00 | $171.72 | 28.4% |
About Dr. Charles Catcher, MD
Dr. Charles Catcher, MD is a Hematology & Oncology healthcare provider based in Concord, New Hampshire. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1114978749.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Charles Catcher, MD has received a total of $91.60 in payments from pharmaceutical and medical device companies, with $32.92 received in 2021. These payments were reported across 5 transactions from 5 companies. The most common payment nature is "Food and Beverage" ($46.23).
As a Medicare-enrolled provider, Catcher has provided services to 2,898 Medicare beneficiaries, totaling 76,343 services with total Medicare billing of $1.4M. Data is available for 2 years (2020–2021), covering 61 distinct procedure/service records.
Practice Information
- Specialty Hematology & Oncology
- Location Concord, NH
- Active Since 05/16/2006
- Last Updated 01/17/2011
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1114978749
Products in Payments
- Perjeta (Biological) $24.73
- KEYTRUDA (Biological) $21.50
- ORGOVYX (Drug) $21.00
- XPOVIO (Drug) $12.45
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Concord
Dr. Sudhathi Chichili, M.d, M.D
Hematology & Oncology — Payments: $21,182
Dr. Walailuk Chaiyarat, Md, MD
Hematology & Oncology — Payments: $19,417
Dr. Elizabeth Odumakinde, M.d, M.D
Hematology & Oncology — Payments: $17,590
Dr. Lesley Martin, M.d, M.D
Hematology & Oncology — Payments: $7,915
Jeanna Walsh, Md, MD
Hematology & Oncology — Payments: $3,449
Meghan Steiner, Md, MD
Hematology & Oncology — Payments: $1,234